All known human adenoviruses are classified as mastadenoviruses, while the ovine adenovirus (OAdV) serotype 7 is the prototype of the atadenoviruses, a proposed new genus. OAdV replicates abortively in human cell types and has potential as a gene transfer vector. However, the function of OAdV nonstructural genes is poorly understood and it is unclear whether OAdV replication might be complemented by a replicating human AdV in coinfected cells. To investigate possible interactions three human cell lines were singly infected with OAdV or human AdV5 or doubly infected. The development of a cytopathic effect and genome replication was monitored over three passages in each cell type. No significant OAdV replication occurred in any of the cell types examined either in the presence or in the absence of replicating AdV5. No aberrant AdV5 genome products were detected in coinfected cells. In contrast, in coinfected cells an OAdV recombinant that expressed the AdV5 E1A gene was able to promote the replication of an AdV5 E1A-deficient mutant, demonstrating trans-complementation between appropriate viruses. These findings have implications for the biosafety of OAdV vectors and their possible utility for enhancing gene delivery.
INTRODUCTION
The ovine adenovirus (OAdV) isolate OAdV287 (Boyle et al., 1994) is the prototype of a proposed new genus of viruses referred to as the atadenoviruses (Benko and Harrach, 1998; Both, 2001) . OAdV has a narrow host range but replicates efficiently in a primary ovine fetal lung cell line, CSL503 (Boyle et al., 1994) . This cell line is also efficiently infected by AdV5 (Xu and Both, 1998) and presumably, therefore, expresses the CAR receptor (Bergelson et al., 1998; Tomko et al., 1997) . The receptor for OAdV has not been identified but is distinct from CAR because AdV5 and OAdV do not compete for entry into CSL503 cells (Xu and Both, 1998) . Nevertheless, OAdV infects a range of human cell types that are also infected by AdV5, but replication is abortive (Khatri et al., 1997) . Depending on the cell type, individual OAdV promoters may be active or inactive, but in all non-ovine cell types examined, the major late promoter (MLP) is not detectably active and no virus is produced (Khatri et al., 1997) . However, OAdV promoters are not well characterized and the basis for their (in)activity in different cell types is not understood. In addition, OAdV lacks an E1A gene homologue and does not have transforming ability in cells that are transformed by AdV5 E1A/B sequences (Xu et al., 2000) , but homologues of E1B and E4 genes appear to be present in the genome (Vrati et al., 1996a) . Several other reading frames that encode putative proteins of unknown function are also present (reviewed in Both, 2001) .
Recombinant OAdVs have been constructed (Vrati et al., 1996b; Xu et al., 1997) to assess the potential of the virus as a gene delivery vector (Löser et al., 2000) . Perceived advantages are that OAdV is not neutralized by random human antisera that neutralize AdV5 and that the vector has an in vivo cell tropism that differs from AdV5 , which may offer new cellular targets for gene delivery. Because the carrying capacity of OAdV exceeds that of AdV5 expression cassettes have generally been inserted into the OAdV genome without a compensating deletion. Thus, most OAdV vectors retain their full gene complement and the issue of where the replication cycle is blocked in human cells and whether it can be complemented in trans is a potential safety issue. Coinfection of cells by a replication-competent human AdV that expresses E1A proteins might produce unintended consequences because E1A products interact with numerous cellular proteins to activate a variety of viral and cellular promoters (Liu and Green, 1994; and reviewed in Shenk, 1996) . Here we investigated whether there was any detectable interaction between OAdV and AdV5, manifested at the level of viral replication, during coinfection of three different cell types. The ability of an OAdV recombinant that expressed the AdV5 E1A gene to complement a replicationdeficient virus that lacked E1A function (Jones and Shenk, 1979) was also examined. Our findings have positive implications for the safety of OAdV vectors and provide an in-principle demonstration that the replication of a de-fective human Ad vector may be enhanced in trans by delivery of the appropriate gene using an OAdV vector.
RESULTS

Infection of MCF7 cells
The potential for interaction between ovine adenovirus OAdV623, a recombinant that carries the complete genome plus an expression cassette (see Materials and Methods), and a replicating human adenovirus, typified by AdV5, was first investigated using MCF7 cells. After infection of these cells with OAdV623 at m.o.i. 70 no significant cytopathic effect (cpe) was seen after 4 days ( Fig. 1A) . Following a further two ( Fig. 1B) or three passages (not shown) OAdV623 again failed to produce cpe. However, infection of MCF7 cells with OAdV217A, which expresses GFP, proved that these cells were infected by OAdV (Fig. 2) , confirming earlier work (Khatri et al., 1997) . In contrast to OAdV, infection by AdV5 produced a complete cpe after 4 days at m.o.i.s of 0.1 and 1.0 ( Fig. 1A) and cpe was also observed after a further two passages ( Fig. 1B) .
After initial infection the AdV5 genome replicated with an efficiency that was easily detectable by ethidium bromide staining (Fig. 3A, lanes 9 and 10) . However, the OAdV623 genome replicated to a level that was greater than input DNA (lanes 2, 5, and 6) but barely detectable, even with a radiolabeled whole-genome probe (Fig. 3B, lanes 8, 11, and 12) . After two passages in MCF7 cells AdV5 DNA remained detectable by staining ( Fig. 3C , lanes 9-12) while OAdV DNA was no longer detectable, even with the radiolabeled probe (Fig. 3D, lanes 8, 11, and 12) . No aberrant AdV5 bands were observed after replication in the presence of the OAdV623 genome following one, two (Figs. 3A and 3C, lanes 11 and 12), or three passages (data not shown). It is estimated from the plasmid standards that the radiolabeled whole-genome OAdV probe used in Fig. 3B would have detected in the range of 150-1500 genome copies per cell (10 ng of OAdV plasmid DNA is ϳ3 ϫ 10 8 genome copies). Thus, if a segment comprising 10% of the OAdV genome had been incorporated into a replicating hybrid AdV5 genome, approximately 1500 copies/cell would have been detectable.
Infection of HeLa and MRC5 cells
The same experiment was carried out in HeLa and MRC5 cells as these are also infected by both viruses (Khatri et al., 1997;  and data not shown). In HeLa cells results essentially identical to those obtained with MCF7 cells were obtained; i.e., the OAdV623 genome did not replicate. However, in MRC5 cells infected with OAdV at high multiplicity (m.o.i. 70), cpe appeared by day 4 as previously reported (Khatri et al., 1997) . This reduced the level of AdV5 replication in doubly infected cells compared with AdV5 infection alone. Again, Southern analysis showed that the OAdV623 genome did not replicate significantly in these cells after initial infection. Thus, the apparent cpe was not due to replication and the virus did not passage. In subsequent passages on MRC5 cells AdV5 replicated normally and the HindIII pattern was unchanged. Southern analysis showed that no portion of the OAdV genome was detectably incorporated into a replicating AdV5 genome (data not shown).
Rescue and characterization of an OAdV recombinant expressing the AdV5 E1A gene
The apparent lack of interaction between OAdV and AdV5 suggested that it would be possible to use OAdV to deliver a gene to complement defective AdV5 replication in coinfected cells. A positive outcome from such an experiment would also act as a control for the negative results obtained above. Therefore a plasmid in which the E1A gene and promoter were inserted into nonessential reading frame RH2 at the right-hand end of the OAdV genome was constructed ) and virus OAdV619B was rescued. The genome of this virus had the expected pattern of BamHI fragments ( Fig. 4 ) in that the plasmid band of 17.8 kb was converted to fragments of 10.3 and 4.2 kb in the virus (the prokaryotic fragment of ϳ3 kb was lost). Expression of the E1A gene after infection of permissive CSL503 cells by OAdV619B was confirmed by immunofluorescence using an E1A-specific monoclonal antibody ( Fig. 5 ). Similar attempts to demon-strate E1A expression in HeLa and MCF7 cells in which OAdV does not replicate did not produce a fluorescent signal above background (data not shown).
Complementation of a defective AdV5 mutant
The ability of OAdV619B to complement AdV dl 312 replication was first examined in HeLa cells. Compared to uninfected cells ( Fig. 6A, well 1) , the cell monolayer was also preserved at day 3 postinfection after HeLa cells were singly infected with m.o.i. 10 of AdV dl312 or OAdV619B (wells 2 and 3) or with m.o.i. 10 or 100 of wild-type OAdV (wells 7 and 8). Cells infected with wild-type AdV5 (0.1 TCID 50 /cell) remained relatively intact at 3 days (well 9) but at m.o.i. 1.0 (well 10) severe cpe was evident as expected. Coinfection with wild-type OAdV and AdV dl312 at m.o.i. 100 and 5 TCID 50 /cell, respectively, produced no obvious cpe (well 6). In contrast, coinfection with m.o.i. 5 or 50 of AdV dl312 plus OAdV619B produced extensive or total cpe, respectively (wells 4 and 5), suggesting that AdV dl312 had replicated due to trans-complementation by E1A. This was confirmed by analysis of the corresponding DNA samples from duplicate cells infected as in Fig. 6A . Ethidium bromide staining ( Fig. 6B ) showed that no HindIII bands were detected in mock-infected cells (lane 1) or cells singly infected with AdV dl 312 (lane 2), OAdV619B (lane 3), or wild-type OAdV (lanes 6 and 7). Consistent with the lack of cpe observed above, viral DNA replication was also not detected in cells coinfected with m.o.i. 50 of AdV dl312 and wild-type OAdV (lane 8). However, AdV dl312 genome replication occurred in the presence of both low (m.o.i. 5) and higher (m.o.i. 50) inputs of OAdV619B (lanes 4 and 5). The presence of the ϳ1.9-kb GЈ band rather than the larger band G is diagnostic for AdV dl312 (Jones and Shenk, 1979) . The level of AdV dl 312 DNA replication at the higher m.o.i. approximated that seen following infection with wild-type AdV5 at m.o.i. 1.0 (lane 10).
The ability of OAdV619B to complement AdV dl312 replication was quantitated by determining virus titers. At day 4 the titer of virus present in the medium of HeLa cells infected with AdV dl312 alone was 10 8 TCID 50 /ml of AdV dl312 when assayed on 911 cells (Table 1) . However, in the presence of an increasing input of OAdV619B AdV dl 312 titers increased by up to 2 log 10 (Table 1) .
Similar experiments were carried out in MCF7 cells and viral titers were again monitored. In several experiments in the presence of OAdV619B AdV dl312 titers again increased over input virus by a maximum of ϳ100and 200-fold at 3 and 6 days postinfection, respectively (Table 1, Fig. 7) , showing that complementation of AdV dl312 replication had also occurred in this cell line. In addition, when the products from these mixed infections were passaged on MCF7 cells in the absence of freshly added OAdV619B, AdV dl312 titers decreased significantly (Fig. 7) , as expected for the passage of defective viruses.
DISCUSSION
OAdV is the prototype of the proposed atadenovirus genus (Benko and Harrach, 1998) and for a variety of reasons, including its neutralization properties and in vivo tropism (Both, 2002; Hofmann et al., 1999; Löser et al., 2000) , there is interest in developing the virus as a gene transfer vector. There are numerous differences between OAdV and the mastadenoviruses genomes but comparatively little is known about the expression and function of nonstructural genes carried by OAdV. An overview transcription map of the genome has been determined (Khatri and Both, 1998) but detailed analyses of promoters and the transcription factors that control them have not been carried out. OAdV replicates abortively in the human cell types that have been tested (Khatri et al., 1997) but the basis for this is not well understood. In a future clinical situation involving gene delivery by OAdV, coinfection by an adventitious human adenovirus could have safety or efficacy implications. Thus, AdV5 was selected as a typical human adenovirus to investigate potential interactions between an OAdV vector and a replication-competent virus.
As infection of human cells with OAdV often shows little phenotypic effect (Khatri et al., 1997) , OAdV217A , a virus that expressed GFP, was used to confirm infection of some cell lines. However, as shown by restriction enzyme and PCR analyses the HCMV/GFP reporter gene cassette inserted in a left to right orientation in site I between pVIII and fiber has proven to be unstable . In addition, the viral major late promoter which might salvage expression is not active in human cells (Khatri et al., 1997) . Thus, OAdV217A must substantially underreport the extent of infection.
The outcome of coinfection with wild-type AdV5 and OAdV623 was examined in three human cell lines with essentially the same results. Although AdV5 replicated to a high level as expected, the OAdV genome was not 3.2 ϫ 10 9 3.2 ϫ 10 7 20 5.9 ϫ 10 9 1.0 ϫ 10 8 50 1 ϫ 10 10 1.7 ϫ 10 7 100 1 ϫ 10 10 1.0 ϫ 10 8 a TCID 50 /ml titered in 911 cells. b TCID 50 /cell titered in CSL503 cells.
significantly replicated after infection in the presence or in the absence of replicating AdV5. Upon passage all trace of OAdV replication was lost. This confirmed earlier work (Khatri et al., 1997) and showed that abortive OAdV replication in human cells was not complemented in trans by any AdV5 gene product, in particular, by AdV5 E1A proteins. However, the effect of E1A expression, if any, on the activity of individual OAdV promoters has not been examined. Several other differences between the OAdV and the AdV5 genomes are consistent with the lack of complementation/interaction between the viruses (Fig. 8) . Compared to AdV5 (a prototype mastadenovirus), the OAdV genome is characterized by a high A/T (low G/C) content, ITRs that are distinct in both length and sequence, the absence of structural proteins V and IX, and a reading frame that encodes the structural protein p32 near the left end of the genome. The distinctive base composition reflects a low nucleotide sequence homology between the two genomes that in turn minimizes the likelihood of homologous recombination between them. Even if this did occur, a single event would yield a hybrid genome with nonidentical ITR sequences and one that would encode an incomplete set of genes for either virus. In the even more unlikely event of two recombination events a genome with identical ITRs could be formed. Potentially this could be amplified by the AdV5 DNA replication machinery. However, the formation of aberrant AdV5 genomes was not observed in any of the cell lines examined, even after multiple passages to allow for genome amplification. The implication from these experiments is that if a virus such as AdV5 coinfected cells containing an OAdV vector, the outcome may well be inconsequential. Together with the lack of transforming ability of OAdV (Xu et al., 2000) , these data have important positive implications for the biosafety of OAdV vectors.
In contrast, to investigate whether complementation between compatible genomes could occur we determined whether an OAdV recombinant that carried the AdV5 E1A gene and promoter could promote the replication of AdV dl312, an E1A-defective mutant (Jones and Shenk, 1979) . The finding that the replication of AdV dl312 increased in both HeLa and MCF-7 cells in response to coinfection with an OAdV vector that expressed the miss-ing gene provided an in-principle demonstration of transcomplementation after coinfection. The positive result also reinforced the lack of compatibility between OAdV and AdV5 genomes implicit in the negative results described above. This demonstration of trans-complementation is consistent with previous work which demonstrated that genes delivered on a plasmid (Goldsmith et al., 1994; Han et al., 1998; Imler et al., 1995; Oualikene et al., 1995) or a coinfecting bovine adenovirus (Zheng et al., 1994) could complement a defect in the AdV5 genome, thus promoting limited replication.
As the replication-deficient virus was propagated in 293 cells that carry integrated E1A/B sequences (Graham et al., 1977) we considered whether contaminating replication-competent AdV5 formed by recombination in those cells might account for the increase in AdV dl312 titers. However, the same amount of AdV dl312 was added to all cells and the effect of complementation by OAdV619B was seen over and above the minimal replicative capacity of AdV dl312 stocks in HeLa and MCF7 cells. The higher level of AdV dl312 recovered from HeLa compared with MCF7 cells may reflect an ability of the former cells to complement the E1A defect in the virus due to the presence of papilloma virus E6/E7 sequences.
Despite the positive outcome for AdV dl312 replication, the conditions for complementation in those experiments may not have been optimal. It was demonstrated by immunofluorescence that E1A proteins were expressed in CSL503 cells during permissive infection by OAdV619B although the level of expression was not quantitated. However, E1A expression was not detectable by immunofluorescence in HeLa and MCF7 cells where OAdV replication was abortive. Thus, the observed complementation was probably achieved with a very low level of E1A. By using a stronger constitutive promoter to drive E1A expression complementation may be enhanced. However, the effect would still be limited by the relative abilities of both OAdV and AdV5 to enter target cells. As the viruses appear to use distinct receptors (Xu and Both, 1998) a deficiency in either receptor would currently limit the applicability of mixed infection to enhance replication.
In principle, the benign outcome of OAdV infection in some cell types could be exploited to deliver a variety of other genes whose products can complement in trans. Expression of AdV5 E1A/B genes is an obvious choice to amplify expression from many existing AdV5 vectors. Construction of such an OAdV vector would be facilitated by the removal of an internal KpnI site in the E1B gene that was limiting in the present circumstances since OAdV genomes are released from plasmids with that enzyme (Vrati et al., 1996b) . The delivery of E4 genes for complementation may also be possible. Similarly, an OAdV that expresses the CAR receptor (Bergelson et al., 1998; Tomko et al., 1997) might also be used to render CAR-negative, OAdV-receptor-positive cells susceptible to infection by existing AdV5 vectors.
MATERIALS AND METHODS
Cells and viruses
CSL503 cells were obtained from CSL Ltd. (Parkville, Victoria, Australia). MCF7 (human breast cancer), HeLa (human cervical carcinoma), and MRC5 (human lung) cells were obtained from ATCC and from Drs. R. Holliday and P. Molloy at CSIRO (North Ryde, New South Wales, Australia), respectively, and grown in DMEM high glucose (Trace Biosciences, Castle Hill, New South Wales, Australia) plus 10% FCS. For MCF7 cells, the FCS was heat-inactivated and for MRC5 cells sodium pyruvate (1 mM) was also added. 911 cells (Fallaux et al., 1996) were obtained from Introgene BV (Leiden, The Netherlands) and grown in DMEM plus 10% heat-inactivated FCS.
Wild-type AdV5 was obtained from ATCC. AdV dl312, obtained from Dr. A. Mullbacher (Australian National University, Canberra) carries an E1A deletion and at low multiplicity of infection is defective for replication (Jones and Shenk, 1979) . Recombinant virus OAdV217A that expresses green fluorescent protein was previously described . Recombinant virus OAdV623 (to be described elsewhere) carries an expression cassette that comprises a prostate promoter linked to the Escherichia coli purine nucleoside phosphorylase coding sequences and a polyadenylation signal inserted in the ApaI/NotI sites of plasmid pOAV600 . This insertion was made at an intergenic site between the transcription units for the right-hand end and the proposed E4 regions (Khatri and Both, 1998) . Virus OAdV619B was constructed by inserting the AdV5 E1A gene and promoter into nonessential reading frame RH2 of the OAdV genome as follows. Plasmid pOAV100 (Vrati et al., 1996b) was digested with SalI and an oligonucleotide containing NotI/ApaI sites was inserted (pOAV608B). Plasmid pE1-FR1 (provided by Dr. R. Garver, Gene Therapy Program, University of Alabama at Birmingham) (Xu et al., 2000) containing AdV5 E1A and E1B sequences in an inverted orientation was cut with EcoRI and XhoI to release the E1A gene and promoter. This fragment was bluntend-cloned into the XbaI site of pGem11zf (Promega Corp., Madison, WI) and a clone with the fragment in the NotI/ApaI orientation was selected. The E1A sequences were subcloned into the NotI/ApaI sites of pOAV608B to create plasmid pOAV619B. This plasmid was digested with KpnI to release the linear OAdV genome and naked DNA was transfected into CSL503 cells to rescue the corresponding virus, OAdV619B (Vrati et al., 1996b) . This virus contains the E1A gene inserted within the nonessential open reading frame RH2 (22.3 kDa) of the genome . Wild-type OAdV, OAdV619B, and OAdV623 with particle:infectious particle ratios of Ͻ100:1 were propa-gated in CSL503 cells and purified by centrifugation in CsCl density gradients (Boyle et al., 1994) . Wild-type AdV5 and AdV dl 312 (ratios of 140:1 and 23:1, respectively) were propagated in 293 cells and similarly purified (Graham and Prevec, 1991) . Viruses were titered in appropriate cell lines by limiting dilution titration. Multiplicity of infection therefore refers to TCID 50 /cell unless specified otherwise.
Infection of cells
OAdV623 replication in the presence and in the absence of AdV5 was examined in MCF7, HeLa, and MRC5 cells. Cells were left uninfected or were infected in triplicate with ϳ70 TCID 50 /cell (10 4 virus particles (vp)/cell) of OAdV623, or 0.1 or 1.0 TCID 50 /cell (7 or 70 vp/cell) of AdV5 or coinfected with the respective amounts of AdV5 and OAdV623. One set of cells was harvested 3 h after infection and low-molecular-weight DNA was extracted as a control for input viral DNA. The remaining cells were incubated for 4 days. One set was used for staining of residual cells with crystal violet. A third set was used for extraction of low-molecular-weight DNA that, along with control samples, was subjected to restriction enzyme digestion and analysis by agarose gel electrophoresis to ascertain whether viral genome replication had occurred. Medium from one set of cells was also retained so that any virus produced by day 4 could be passaged on fresh cells. Three passages were carried out.
To monitor interaction between OAdV619B and AdV dl312, cells were singly or doubly infected and harvested at days 3-6 postinfection as indicated for each experiment. Cells were processed as described above or a sample of the medium was taken for the determination of AdV dl312 titers using a limiting dilution assay on 911 cells.
Immunofluorescence with M73
Monoclonal antibody M73 (Harlow et al., 1985) was obtained from Dr. A. Mullbacher (Australian National University, Canberra). E1A expression was detected by immunofluorescence. Briefly, cells were washed in PBS, fixed in 4% paraformaldehyde in PBS, washed again, made permeable with 1:1 methanol:acetone, and washed in PBS. A 1:5 dilution of M73 was added to cells for 2 h at 37°C and excess antibody was removed by washing with PBS. E1A/M73 complexes were detected by fluorescence microscopy after being stained with FITC-conjugated rabbit anti-mouse serum (Dako) (1 in 20 dilution).
Preparation and analysis of low-molecular-weight DNA
At 3-5 days postinfection cells in the medium were spun down and combined with residual attached cells. Viral genomic DNA was recovered as previously de-scribed (White et al., 1984) . Briefly, cells were treated with pronase/SDS and residual DNA was recovered and adjusted to 1 M NaCl to precipitate high-molecularweight DNA. Low-molecular-weight DNA was recovered from the supernatant by precipitation with ethanol, digested with HindIII, and analyzed by agarose gel electrophoresis.
Preparation of genomic probes
Radiolabeled probes of the OAdV or AdV5 genomes were prepared by using a Gigaprime kit (Geneworks, Adelaide, South Australia, Australia) to randomly label 25 ng of the plasmids pOAdV220 or pJM17 (McGrory et al., 1988) , respectively. The latter plasmid comprises the entire AdV5 genome with a prokaryotic insert in the E1 region. The restriction enzyme profiles of the plasmids differ from those of the corresponding virus because the plasmids also carry a prokaryotic ampR gene and origin of DNA replication. These are similar and cross-hybridize.
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